Bismuth H, Adam R, Raccuia J S
Centre Hepato-Biliaire, Hôpital Paul Brousse, Villejuif, Frankreich.
Chirurg. 1995 Jun;66(6):574-81.
We reviewed 1000 consecutive liver transplants over a 10 year period with special attention to a pre-transplant history of portal hypertension revealed by variceal hemorrhage. Of 730 primary transplanted patients with chronic liver disease 186 (26%) experienced variceal bleeding prior to transplantation of which 130 (70%) required interventional therapy to palliate the bleeding. Sclerotherapy was performed in 93 (50%), surgical portal diversion in 27 (15%) and TIPSS in 10 (5%) patients. Moderate to severe liver dysfunction accounted for 91% of the patients with bleeding complications. The impact of both bleeding and treatment modality utilized in the pre-transplant period was analyzed in a way to integrate liver transplantation into the multimodality treatment of portal hypertension. The overall survival for all patients was 76% at five years. Previous history of variceal bleeding did not affect the outcome of patients following liver transplantation. The patients treated by initial sclerotherapy demonstrated no difference with either graft or patient survival. The patients who had TIPSS to control hemorrhage had lower, but insignificant, graft and patient survival. The group of patients with variceal hemorrhage who had prior surgical shunt did, however, demonstrate a significant increased survival of 96% when compared to the non-shunted group which had a 73% survival (p < 0.007). The strategy in treating these potential transplant patients is critical to the success of the subsequent transplant.
我们回顾了10年间连续进行的1000例肝移植病例,特别关注因静脉曲张出血而揭示的移植前门静脉高压病史。在730例患有慢性肝病的初次移植患者中,186例(26%)在移植前发生了静脉曲张出血,其中130例(70%)需要介入治疗以缓解出血。93例(50%)患者接受了硬化治疗,27例(15%)接受了手术门体分流,10例(5%)患者接受了经颈静脉肝内门体分流术(TIPSS)。中度至重度肝功能不全占出血并发症患者的91%。分析了移植前期出血及所采用治疗方式的影响,以便将肝移植纳入门静脉高压的多模式治疗中。所有患者的五年总生存率为76%。既往静脉曲张出血史并未影响肝移植患者的预后。最初接受硬化治疗的患者在移植物或患者生存率方面与其他患者无差异。接受TIPSS控制出血的患者移植物和患者生存率较低,但无统计学意义。然而,与未行分流术且生存率为73%的患者组相比,既往接受过手术分流术的静脉曲张出血患者组生存率显著提高,达96%(p < 0.007)。治疗这些潜在移植患者的策略对后续移植的成功至关重要。